Mario Mandala
Expertise in
4
conditions

Mario Mandala

Perugia, IT 
Expertise in
4
conditions
Perugia, IT 
OverviewLocationsClinical Research

Overview

Mario Mandala practices in Perugia, Italy. Mr. Mandala is highly rated in 4 conditions, according to our data. His top areas of expertise are Melanoma, Venous Thromboembolism (VTE), Metastatic Brain Tumor, and Gastroesophageal Junction Cancer.

His clinical research consists of co-authoring 241 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Perugia, 06156, Italy
Other Locations
Siena, 53100, Italy
Rende, Italy
Bergamo, Italy
Santa Maria, Italy
Azienda Ospedaliero Careggi, Toscana
Florence, Italy
Verona, Italy
Treviglio, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN)
Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN)
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Drug
Study Drugs: Nivolumab + Ipilimumab, Encorafenib + Binimetinib
Study Phase: Phase 2
A Phase II, Single Arm Study Investigating Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in High Risk, Surgically Resectable, Stage III Cutaneaous Squamous Cell Carcinoma
A Phase II, Single Arm Study Investigating Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in High Risk, Surgically Resectable, Stage III Cutaneaous Squamous Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drug: Cemiplimab
Study Phase: Phase 2
A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation
A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation
Enrollment Status: Completed
Publish Date: June 07, 2024
Intervention Type: Drug
Study Drugs: LGX818, MEK162, Nivolumab, Ipilimumab
Study Phase: Phase 2
Adjuvant Immunotherapy in Patients With Resected Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): an Open Label Randomized Controlled Phase-2-study
Adjuvant Immunotherapy in Patients With Resected Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): an Open Label Randomized Controlled Phase-2-study
Enrollment Status: Active_not_recruiting
Publish Date: January 05, 2024
Intervention Type: Drug, Other
Study Drug: Nivolumab+Ipilimumab
Study Phase: Phase 2
Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial
Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial
Enrollment Status: Unknown
Publish Date: September 28, 2023
Intervention Type: Drug
Study Drugs: CAPOX, Capecitabine, FOLFIRI
Study Phase: Phase 2
View 4 Less Clinical Trials

241 Total Publications

Tumour microenvironment heterogeneity in primary and metastatic paired melanoma samples and its correlation with genetic features and prognosis.
Tumour microenvironment heterogeneity in primary and metastatic paired melanoma samples and its correlation with genetic features and prognosis.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Mandala's expertise for a condition
ConditionClose
    View All 19 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile